Not currently recruiting at UCSF
Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
Summary
- Eligibility
- for people ages 12-75 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients at some sites,
but this study is not currently recruiting here - Start Date
- Completion Date
- (estimated)
- Sponsor
- Mitsubishi Tanabe Pharma Development America, Inc.
- ID
- NCT05005975
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 175 study participants
- Last Updated